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Abstract
Background: Although systemic corticosteroid (SCS) treatment, irrespective of dura-
tion or dosage, is associated with adverse outcomes for patients with asthma, the
longitudinal effects of this treatment on adverse outcomes, healthcare resource
utilization (HCRU), and healthcare costs are unknown.
Methods: We identified patients initiating intermittent or long‐term SCS who were
diagnosed with active asthma from UK general practice with linked secondary care
data. Control (non‐SCS) patients were matched by sex and index date with those
initiating SCS. Minimum baseline period was 1 year prior to index date; minimum
follow‐up duration was 2 years post–index date. Cumulative incidence of SCS‐asso-
ciated adverse outcomes and associated HCRU and costs were compared between
SCS and non‐SCS patient groups and among average SCS daily exposure categories.
Associations between exposure and annualized HCRU and costs were assessed,
adjusted for confounders.
Results: Analyses included 9413 matched pairs. Median (interquartile range) follow
up was as follows: SCS group: 7.1 (4.1‐11.8) years; control group: 6.4 (3.8‐10.0)
years. Greater SCS dosages were correlated with greater cumulative incidence. For
example, patients with type 2 diabetes receiving an average daily dosage of
≥7.5 mg had a 15‐year cumulative incidence (37.5%) that was 1.5‐5 times greater
than those receiving lower dosages. HCRU and costs increased annually for SCS
patients but not for non‐SCS patients. Increases in all‐cause adverse outcome
(excluding asthma)–associated HCRU and costs were dose‐dependent.
Conclusions: Over the long term, adverse outcomes associated with SCS initiation
were relatively frequent and costly, with a positive dosage–response relationship
with SCS exposure.
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1 | INTRODUCTION
Frequent short‐ or long‐term corticosteroid use is associated with
substantial adverse effects, including osteoporosis, peptic ulcers, cat-
aracts, adrenal suppression, weight gain, hyperglycemia, hyperten-
sion, mood problems, and diabetes.1-4 For example, Iribarren et al2
reported the risks of coronary heart disease and all‐cause mortality
increased 2.5‐ and 2.6‐fold, respectively, for patients with asthma
compared with matched controls. This was driven by asthma‐
associated oral corticosteroid (OCS) use. In addition, the increased
risk of adverse effects is dependent on corticosteroid dosage.2,5-8
Dalal et al8 found that long‐term corticosteroid users (≥6 months)
with low‐ (<5 mg/day), medium‐ (≥5‐10 mg/day), and high‐dosage
(>10 mg/day) exposure had, respectively, a 2.5‐, 2.95‐, and 3.32‐fold
greater adjusted relative risk of developing any steroid‐related com-
plication compared with steroid nonusers.
However, all previous studies had a relatively short baseline per-
iod that prevented true identification of systemic corticosteroid
(SCS) initiators and, consequently, the study of longitudinal effects
of SCS use from its initiation on adverse outcomes.1-8 Furthermore,
the longest follow‐up period in previous studies was only up to
4 years, prohibiting the study of long‐term impact of corticosteroid
use on adverse outcomes. There are limited data available on the
longitudinal impact of SCS exposure on healthcare systems, although
the effect of SCS use on short‐term healthcare resource utilization
(HCRU) and associated costs has begun to be reported in the litera-
ture.8,9 In an analysis of adverse drug events (ADEs) in hospitals,
Weiss and colleagues9 found corticosteroid use to be among the top
three causes of ADEs associated with hospital admission in the
United States. Using a commercial database in the United States,
Dalal et al8 found adjusted annual, incremental, steroid‐related
complication costs of $2670, $4639, and $9162 (2014 US $) over a
1.5‐year median follow‐up period for long‐term low‐, medium‐, and
high‐dosage steroid users, respectively, compared with nonusers.
In this study, we compared the long‐term incremental risks of
adverse outcomes and their associated HCRU and costs for patients
with asthma who did and did not initiate SCS (parenteral corticosteroid
or OCS) and who had complete primary and secondary HCRU data.
Furthermore, we explored how healthcare costs changed over time.
2 | METHODS
Additional details regarding the methods for cost estimations, mea-
sures and definitions, and statistical analyses are contained in the
Appendices A-D, Tables S1-S6.
2.1 | Data source
We conducted a matched, historical cohort study using data from
using the Clinical Practice Research Datalink (CPRD) database. The
CPRD contains longitudinal data from 5 million active medical
records from more than 600 subscribing practices throughout the
United Kingdom. The CPRD data set contains patient records from
June 1994 through January 2015, with 39% of patient data linked
to Hospital Episode Statistics (HES), a data warehouse containing
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complete and reliable information on inpatient hospital admissions,
with linkage available from April 1997 through February 2016.10
CPRD also includes information from general practice (GP) visits.
Public health researchers have used CPRD, formerly known as the
General Practice Research Database, since 1987.11 This study
involved anonymized patient data that did not require ethics board
approval, and was approved by the CPRD Independent Scientific
Advisory Committee (reference number 17_002).
2.2 | Study design and patients
The study used a minimum 1‐year baseline period and a minimum 2‐-
year outcome (follow‐up) period. The index date was the date of the
first recorded prescription for a parenteral corticosteroid or OCS in the
SCS arm, whereas for the non‐SCS arm, it was the nearest GP visit to
the matched‐case index date. We matched non‐SCS patients to SCS
patients 1:1 by sex, availability of HES linkage, and index date. SCS
TABLE 1 Demographics and baseline clinical characteristics of
HCRU analysis cohort (overall SCS population)
Variable
SCS
(n = 9413)
Non‐SCS
(n = 9413)
SMD
(%)
Sex (male), n (%) 3268 (34.7) 3268 (34.7) 0.0
Age categories (years), n (%)
18‐40 3284 (34.9) 4890 (51.9) 28.6
41‐60 3468 (36.8) 2593 (27.5)
61‐80 2378 (25.3) 1618 (17.2)
>80 283 (3.0) 312 (3.3)
BMI (kg/m²), closest in 5 years prior, categorized, n (%)
N (% nonmissing) 6511 (69.2) 6757 (71.8) 19.2
<18.5 140 (2.2) 183 (2.7)
18.5‐<25 2180 (33.5) 2816 (41.7)
25‐<30 2127 (32.7) 2092 (31.0)
≥30 2064 (31.7) 1666 (24.7)
Uncontrolled asthma,a,b n (%) 2863 (30.4) 1253 (13.3) 42.3
Severe asthma year prior,b,c n (%) 3794 (40.3) 2043 (21.7) 41.1
Hospitalization with asthma year
prior,b,d n (%)
106 (1.1) 35 (0.4) 8.8
A&E with asthma year prior,b,e
n (%)
71 (0.8) 32 (0.3) 5.6
High‐dosage ICS year prior,f n (%) 582 (6.2) 365 (3.9) 10.6
SCS refills per year,g n (%)
<1 2342 (28.4) NA NA
1‐<2 2777 (33.7) NA NA
2‐<3 1443 (17.5) NA NA
3‐<4 694 (8.4) NA NA
4‐<7 636 (7.7) NA NA
≥7 348 (4.2) NA NA
Hypertension diagnosis,h n (%) 1628 (17.3) 1325 (14.1) 8.9
Depression diagnosis,h n (%) 2842 (30.2) 2436 (25.9) 9.6
Peptic ulcer diagnosis,h n (%) 200 (2.1) 155 (1.6) 3.5
Dyslipidemia diagnosis or elevated
lipids,h,i n (%)
1234 (13.1) 1065 (11.3) 5.5
Type 2 diabetes mellitus diagnosis
or 2x HbA1c ≥6.5%,h n (%)
370 (3.9) 458 (4.9) 4.6
Cardio‐cerebrovascular disease
(MI, HF, CVA) diagnosis, ever
prior, n (%)
382 (4.1) 364 (3.9) 1.0
MI diagnosis 165 (1.8) 144 (1.5) 1.8
HF diagnosis 95 (1.0) 119 (1.3) 2.4
CVA diagnosis 162 (1.7) 167 (1.8) 0.4
Glaucoma diagnosis, ever prior,
n (%)
114 (1.2) 106 (1.1) 0.8
Sleep apnea diagnosis, ever prior,
n (%)
23 (0.2) 19 (0.2) 0.9
Cataract diagnosis or surgery, ever
prior, n (%)
327 (3.5) 303 (3.2) 1.4
Osteoporosis diagnosis, ever prior,
n (%)
145 (1.5) 121 (1.3) 2.2
(Continues)
TABLE 1 (Continued)
Variable
SCS
(n = 9413)
Non‐SCS
(n = 9413)
SMD
(%)
Renal impairment, eGFR‐based stage, closest prior, n (%)
Stage 3a to Stage 5, eGFR <60 933 (9.9) 807 (8.6)
Pneumonia diagnosis, year prior,
n (%)
50 (0.5) 25 (0.3) 4.2
Charlson comorbidity index, new weights, n (%)15
0‐4 3881 (41.2) 3852 (40.9)
5‐8 4304 (45.7) 4400 (46.7)
9‐12 329 (3.5) 315 (3.3)
13‐16 386 (4.1) 308 (3.3)
≥17 513 (5.4) 538 (5.7)
A&E, accident and emergency; BMI, body mass index; CVA, cerebrovas-
cular accident; eGFR, estimated glomerular filtration rate; FEV1, forced
expiratory volume in 1 second; FVC, forced vital capacity; GINA, Global
Initiative for Asthma; HbA1c, glycosylated hemoglobin; HCRU, healthcare
resource utilization; HES, Health Episode Statistics database; HF, heart
failure; ICS, inhaled corticosteroids; IQR, interquartile range; LDL,
low‐density lipoprotein cholesterol; MI, myocardial infarction; NA, not
applicable; SCS, systemic corticosteroids; SD, standard deviation; SMD,
standardized mean differences; TC, total cholesterol; TG, triglycerides.
aUncontrolled asthma defined as either poor symptom control (either
Asthma Control Questionnaire score >1.5, Asthma Control Test score
<20, or “not well control” based on National Asthma Education and
Prevention Program or GINA guidelines), frequent severe exacerbations
requiring ≥2 bursts of SCS for >3 days in the previous year, serious
exacerbation requiring at least one hospitalization, intensive care unit
stay, or mechanical ventilation in the previous year, or airflow limitation
(prebronchodilator FEV1 <80% predicted in the presence of FEV1/FVC
less than lower limit of normal).
bBased on HES data.
cSevere asthma defined as GINA Step 4/5 or uncontrolled asthma.
dHospitalization with asthma/lower respiratory code on same day.
eA&E with asthma/lower respiratory code on same day.
fHigh‐dosage ICS defined as >500 μg/day fluticasone equivalent.
gBased on follow‐up period, N = 8240.
hAny prior diagnosis ever.
iDefined as TC >6.5, LDL >4, or TG ≥2.3.
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dosages were standardized into prednisolone equivalents (Table S3).
To account for all HCRU outcomes, we included only the subset of
unbroken matched pairs of active asthma patients with HES linkage in
the final study population.10 We followed patients in both arms from
the index date to the end of follow‐up (ie, death, leaving the primary
care practice, end of available records, or last date of extraction).
Patients in the SCS arm were ≥18 years old at first SCS prescrip-
tion and had ≥1 SCS prescription within 18 months after first SCS
prescription. Patients could not have a diagnosis of adrenal insuffi-
ciency/Addison's disease at any time, diagnosis of cancer 5 years
before or 3 months after index date, or tamoxifen prescriptions for
breast cancer at any time.
To evaluate the impact of SCS on the onset of an individual
adverse outcome of interest, we removed patients having the individ-
ual adverse outcome of interest before the index date. Then, we
removed patients who were left without a paired counterpart.
As such, the analysis samples for the different SCS‐related risk cohorts
were dissimilar. Adverse outcomes evaluated are listed in Table S4.
Given that asthma‐related costs are highly driven by disease severity
and not necessarily by SCS‐associated adverse outcomes, we reported
HCRU and costs associated with all‐cause (Table S5) adverse out-
comes excluding asthma and those associated with asthma (defined as
reported with an asthma or lower respiratory disease code) separately.
Inclusion of asthma‐related costs in all‐cause adverse outcome–associ-
ated costs would make the data very difficult to interpret.
2.3 | Statistical analyses
HCRU and associated costs were assessed annually, and annual
averages for the entire follow‐up period were calculated. We esti-
mated HCRU‐associated all‐cause and cause‐specific costs (2016 £)
by multiplying HCRU outcomes by the estimated unit costs associ-
ated with each HCRU outcome from the Personal Social Services
Research Unit,12 National Health Service reference costs,13 and the
Dictionary of Medicines and Devices browser.14 Prescription cost
was obtained by multiplying cost by amount prescribed. Annualized
HCRU and healthcare costs were reported.
We used generalized estimating equations with cluster‐robust
standard errors, log link, and gamma distribution to estimate the
effect of SCS initiation on annualized HCRU or costs found by boot-
strapping using 1000 random samples taken, with replacement, and
adjusted for potential confounders. Besides reporting on adjusted
mean, we also compared SCS and non‐SCS patients using incidence
rate ratio (IRR) for resources and cost ratios for cost with a 95% CI.
Age and sex were used as forced covariates, and the remaining
covariates were selected based on their incremental bias potential.
3 | RESULTS
Of 24 117 matched pairs of asthma patients, 16 623 pairs came
from the CPRD database. Of these, the patients with an HES linkage
were selected, and the ones who lost their matched pair were
removed, resulting in 9413 total matched pairs that were included in
all analyses of this study. A comparison of baseline characteristics
showed that the subset of patients with available HES linkage was
not meaningfully different from the subset of patients without HES
linkage (data not shown).
Of patients included in this study, fewer than 10% had <2 years
and half had ≥8 years of medical record history available before the
index date. Patients had an average of 8.6 years of follow‐up
(median [interquartile range {IQR}]: 7.1 [4.1‐11.8]) in the SCS arm and
an average of 7.7 years (median [IQR]: 6.4 [3.8‐10.0]) in the non‐SCS
arm. In the SCS arm, 11.9% of patients had ≥4 refills of SCS per year;
median daily dosage of the SCS prescribed was 10 mg, and median
total dosage prescribed in one prescription was 200 mg.
Female patients comprised two‐thirds (65.3%) of patients (Table 1).
SCS‐initiating patients were older than patients in the non‐SCS arm
(49 vs 43 years) and had worse lung function (percent predicted nor-
mal 72.8% vs 82.9%) (Table 1). In addition, a greater percentage of
SCS‐initiating patients had severe asthma (defined as Global Initiative
for Asthma [GINA] Step 4/5 OR uncontrolled asthma) based on HES
linkage (40.3% vs 21.7%) and prior‐year hospitalization for asthma
(1.1% vs 0.4%) than control patients. The baseline comorbidities were
similar between the arms (standardized mean differences <10%).
3.1 | Cumulative incidence of adverse outcomes
To assess the occurrence of adverse outcomes associated with SCS
exposure, we examined cumulative incidence among patients who
had no recorded history of that specific outcome at baseline. Regard-
less of SCS dosage, 15‐year cumulative incidence was higher in the
SCS arm than in the non‐SCS arm (eg, renal impairment: 27.9% vs
12.5%; type 2 diabetes: 9.5% vs 5.6%, respectively; Figure S1). Other
adverse outcomes followed a similar trend. The 15‐year cumulative
incidences in the SCS vs non‐SCS arm, respectively, were as follows:
pneumonia, 11.3% vs 3.5%; cataracts, 11.0% vs 4.4%; cerebrovascu-
lar accident, 10.0% vs 5.1%; cardio‐cerebrovascular disease, 9.9% vs
3.6%; osteoporosis, 8.0% vs 2.0%; myocardial infarction, 7.3% vs
2.8%; heart failure, 3.6% vs 1.1%; and glaucoma, 3.4% vs 1.7%.
Greater SCS dosages were also correlated with greater cumula-
tive incidence. For example, for type 2 diabetes, SCS patients with
an average daily dosage of ≥7.5 mg had a 15‐year cumulative inci-
dence of 37.5%, which was 1.5‐5 times greater than that of patients
receiving <0.5 mg/day (cumulative incidence, 7.0%), 0.5‐<2.5 mg/day
(11.3%), 2.5‐<5.0 mg/day (16.3%), and 5.0‐<7.5 mg/day (25.0%) (Fig-
ure S2). For patients with an average exposure of 2.5‐5 mg/day,
which corresponds to three steroid bursts per year, in a 5‐, 10‐, and
15‐year period, 5%, 10%, and 16% of these patients would develop
type 2 diabetes, respectively (Table S7). Similar trends were
observed for all other adverse outcomes (data not shown).
3.2 | Healthcare resource utilization
SCS‐initiated patients with asthma had substantially greater fre-
quency of all‐cause adverse outcome–associated (excluding
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asthma‐related) HCRU and asthma‐related HCRU than patients
without SCS initiation (Table 2). The adjusted IRRs (95% CI) shown
in Figure 1A for SCS initiation vs non‐SCS were 1.22 (1.19‐1.25)
for GP visits, 1.12 (1.06‐1.18) for specialist visits, 1.14 (1.06‐1.23)
for hospitalization, 1.26 (1.16–1.36) for accident and emergency
(A&E) attendances, and 1.35 (1.27‐1.43) for primary care prescrip-
tions. All HCRU types showed a positive dosage–response rela-
tionship with the mean number of adverse outcome–associated
resources used, except the A&E attendances (Figure 1B, reference
lowest dosage [<0.5 mg/day]). At an average dosage of 2.5 mg/
day, patients initiating SCS started yielding a doubling of HCRU
outcomes compared with patients not initiating SCS. Exposure to
SCS at an average dosage of ≥7.5 mg/day resulted in 2.3‐3.0
times greater HCRU from adverse outcomes compared with no
exposure (Table 2).
3.3 | Healthcare resource utilization–associated
costs
All‐cause (excluding asthma) costs associated with adverse outcomes
remained constant over the follow‐up period in the non‐SCS arm,
but these costs increased over time in the SCS arm (Figure S3).
Incremental all‐cause adverse outcome–associated yearly costs for
SCS patients were 7% greater in the first year and 50%, 70%, and
110% greater by Years 5, 10, and 15, respectively. Similar patterns
were observed for asthma‐related costs, although they were not as
striking (Figure S3). When SCS use was categorized by mean average
daily exposure (eg, >0‐<0.5 mg), similar all‐cause adverse outcome–
associated and asthma‐related costs patterns to the overall SCS
patients were observed (data not shown).
Compared with no SCS exposure, SCS use was associated with
greater all‐cause adverse outcome–associated healthcare costs
(adjusted cost ratio [95% CI]: 1.16 [1.10‐1.23], P < 0.001) and
asthma‐related healthcare costs (2.21 [2.13‐2.29], P < 0.001)
(Figure 2A). Adverse outcome–related cost differences were largest
for pneumonia, and overall costs were about 2.3 times greater for
the SCS arm than the non‐SCS arm. Associated average annual costs
for adverse outcomes and asthma were £1483 and £403 for SCS
patients compared with £1165 and £166 for non‐SCS patients,
representing 42% greater overall costs, respectively. Among the
adverse outcome–associated costs, key cost drivers were cardio‐
cerebrovascular diseases, dialysis, and pneumonia.
There was a positive dosage–response association between the
SCS exposure and adverse outcome–associated annual costs. The cost
ratio (95% CI) was 1.25 (1.18‐1.31) for 0.5‐<2.5 mg/day, 1.78 (1.58‐
2.00) for 2.5‐<5.0 mg/day, 2.27 (1.53‐3.36) for 5.0‐<7.5 mg/day,
2.41 (2.02‐2.88) for 7.5‐<15.0 mg/day, and 3.86 (2.53‐5.89) for
≥15.0 mg/day for the SCS arm compared with the non‐SCS arm.
Hospitalization and prescriptions were the largest contributors to
HCRU differences; cost ratio (95% CI) was 4.92 (2.70‐8.97) for hospi-
talization and 8.12 (3.93‐16.75) for prescriptions in the SCS arm
exposed to an average daily dosage of ≥15 mg (all P‐values <0.001)
(Figure 2B). We observed doubling of non‐SCS arm annual risk out-
come–associated costs in the SCS arm starting at 2.5 mg/day (Table 3,
Figure 3). Patients who were exposed to ≥7.5 mg/day SCS had a
£3226 annual cost of adverse outcomes and a £1188 annual cost of
asthma, which combined was 3.3 times greater than for non‐SCS
patients.
We found that when compared with patients who were exposed
predominantly to acute SCS dosages (those in the lowest quartile of
TABLE 2 Mean (SD) annualized HCRU for all‐cause adverse outcomes and asthma
HCRU
No SCS Overall SCS
Mean average daily exposure (mg)
>0‐<0.5 0.5‐<2.5 2.5‐<5.0 5.0‐<7.5 7.5‐<15.0 ≥15.0
n = 9413 n = 9413 n = 5152 n = 3497 n = 436 n = 174 n = 134 n = 20
All‐cause adverse outcome–associated HCRU (excluding asthma‐related)
General practitioner
visits
9.18 (7.76) 12.42 (8.73) 10.55 (7.90) 13.79 (8.87) 17.54 (10.65) 19.81 (12.66) 20.09 (12.15) 28.45 (17.17)
Specialist visits 1.17 (1.94) 1.47 (2.91) 1.29 (2.15) 1.55 (2.37) 1.93 (2.92) 2.54 (4.35) 2.72 (3.59) 3.10 (5.90)
Hospitalizations 0.32 (1.94) 0.40 (0.97) 0.33 (0.72) 0.44 (0.59) 0.68 (1.04) 0.78 (2.11) 0.84 (1.04) 1.48 (2.01)
Accident and
emergency visits
0.15 (0.97) 0.20 (0.97) 0.18 (0.72) 0.23 (0.59) 0.23 (0.63) 0.21 (0.40) 0.26 (0.69) 0.90 (1.79)
Prescriptions 10.08 (23.28) 14.04 (24.26) 11.37 (23.69) 15.32 (23.65) 23.09 (24.85) 30.82 (37.46) 28.38 (22.23) 39.42 (31.75)
Asthma‐related HCRU
General practitioner
visits
1.34 (1.94) 2.65 (1.94) 2.01 (1.44) 3.21 (1.77) 4.23 (2.92) 4.44 (3.30) 4.37 (3.24) 6.26 (3.53)
Specialist visits 0.07 (0.97) 0.23 (0.97) 0.12 (0.72) 0.26 (1.18) 0.70 (1.67) 0.91 (4.35) 1.13 (1.74) 3.10 (6.89)
Hospitalizations 0.00 (0.00) 0.02 (0.00) 0.01 (0.00) 0.03 (0.00) 0.06 (0.21) 0.04 (0.13) 0.21 (1.39) 0.33 (0.45)
Accident and
emergency visits
0.00 (0.00) 0.01 (0.00) 0.01 (0.00) 0.01 (0.00) 0.02 (0.21) 0.00 (0.00) 0.04 (0.35) 0.05 (0.22)
Prescriptions 5.35 (5.82) 10.61 (9.70) 7.85 (7.18) 12.59 (9.46) 19.01 (13.36) 21.31 (15.43) 21.23 (15.05) 25.62 (17.62)
HCRU, healthcare resource utilization; SCS, systemic corticosteroids; SD, standard deviation.
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the refill rate), patients most likely on maintenance dosages of SCS
(those in the highest quartile of the refill rate) incurred greater costs.
Thus, maintenance SCS use seems to be associated with greater
costs compared with acute SCS use (data not shown).
4 | DISCUSSION
In this report, we present the longitudinal effects of SCS treatment,
irrespective of duration or dosage, on adverse outcomes, HCRU, and
healthcare costs. This study was distinct from previous studies in
terms of the availability of data prior to index date (50% with
≥8 years of data), allowing for a more accurate assessment of base-
line SCS use and therefore identification of SCS initiators, and the
long duration of its follow‐up period. We found a dose‐dependent
increase in adverse outcomes, HCRU, and healthcare costs associ-
ated with SCS usage. To the best of our knowledge, this is the first
study to report the long‐term ramifications of SCS usage, both acute
and long‐term, on these parameters and to present these results as a
function of SCS dosage.
Patients with severe, uncontrolled asthma are more likely to use
OCS frequently than patients with moderate disease.16,17 Approxi-
mately 30%‐40% of patients with severe asthma regularly use OCS
to control their disease (intermittently or long term).16-20 Prior
Primary care prescriptions
(A)
(B)
Association with SCS vs non-SCS
A&E attendances
Hospitalizations
Specialist consultations
GP consulations
Incidence rate ratio
1.0 1.1 1.2 1.3 1.4 1.5Adjusted
Unadjusted
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      Primary care prescriptions
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      A&E attendances
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      Hospitalizations
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      Specialist consultations
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      GP consultations
Association with SCS average daily exposure
Incidence rate ratio
0.9Adjusted 1.0 1.5 2.5 3.52.0 3.0 4.0
Unadjusted
F IGURE 1 Incidence rate ratio of
HCRU for all SCS‐related adverse
outcomesa by SCS status and average daily
exposureb. aExcluding asthma. Error bars
represent 95% confidence interval. For
adjustment, age and sex were used as
forced covariates, with BMI, smoking
status, antibiotic‐treated infections, airflow
limitation, asthma medication used (general
and specified), intensive care unit stay,
mechanical ventilation usage, and diagnosis
of and/or treatment for diseases (Table S6)
selected based on their incremental bias
potential. bReference categories for daily
exposure were for the lowest dosage
(<0.5 mg/day). A&E, accident and
emergency; BMI, body mass index; GP,
general practice; SCS, systemic
corticosteroids [Colour figure can be
viewed at wileyonlinelibrary.com]
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studies have indicated an increased risk of adverse outcomes associ-
ated with SCS use, but none have used longitudinal data to quantify
cumulative incidence.
We found that SCS initiation compared with non‐SCS initiation is
associated with substantially greater cumulative incidence of adverse
outcomes, resulting in greater healthcare burden, and there is a posi-
tive dosage–response relationship between cumulative incidence of
adverse outcomes and amount of SCS exposure. Increased risks of
adverse outcomes over time means that SCS use can accrue a con-
siderable, long‐term healthcare burden.
Using British Thoracic Society treatment guidelines of 30 mg/day
for 14 days per exacerbation, we estimated that patients with severe
asthma (assumed to have had ≥3 exacerbations in a year without
long‐term SCS use) are exposed to 1.26 g of corticosteroids per year
(or 3.45 mg/day).21 Even with three steroid bursts per year, over the
long term, these patients would have elevated risks of developing
type 2 diabetes, osteoporosis, cataracts, or having at least one car-
dio‐cerebrovascular disease episode. This circumstance represents a
tremendous long‐term public health issue and healthcare burden
associated with SCS use. Clinicians should therefore consider treat-
ing their patients with steroid‐sparing agents to reduce the risks
associated with SCS use.
Although previous studies documented increased risks of corti-
costeroid‐related onset of chronic complications, they examined dif-
ferent patient populations. Previous studies also did not explore the
effect of dosage and duration of SCS exposure on chronic disease
Cataract
Association with SCS vs non-SCS
Myocardial infarction
Osteoporosis and fracture
Type 2 diabetes mellitus
Asthma
Cost ratio
1.00.90.8 1.5 2.0 2.5Adjusted
Unadjusted
3.0
Peptic ulcer
Renal impairment
Heart failure
Glaucoma
Osteoporosis 
All-cause adverse outcomes-associated
(A)
(B)
Pneumonia
Dialysis
Cerebrovascular accident
Cardio-cerebrovascular disease
Adjusted
Unadjusted
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      Primary care prescriptions
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      A&E attendances
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      Hospitalizations
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      Specialist consultations
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      GP consultations
≥7.5 mg/d
5.0-<7.5 mg/d
2.5-<5.0 mg/d
0.5-<2.5 mg/d
Reference      All resources
Association with SCS average daily exposure
Cost ratio
0.9 1.0 1.5 2.0 3.0 3.5 5.02.5 4.0 6.0
F IGURE 2 Association of all‐cause
adverse outcomea–related costs with SCS
status and average daily exposure.
aExcluding asthma. Error bars represent
95% confidence interval. For adjustment,
age and sex were used as forced
covariates, with BMI, smoking status,
antibiotic‐treated infections, airflow
limitation, asthma medication used (general
and specified), intensive care unit stay,
mechanical ventilation usage, and diagnosis
of and/or treatment for diseases (Table S6)
selected based on their incremental bias
potential. BMI, body mass index; SCS,
systemic corticosteroids [Colour figure can
be viewed at wileyonlinelibrary.com]
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onset, associated disease prevalence, and HCRU and costs for
patients with asthma.22-26 Sullivan et al22 observed an increase in
the odds ratio of new adverse events combined with greater SCS
use (1.04 vs 1.29 for 1‐3 vs ≥4 prescriptions within the year), con-
sistent with our findings for individual adverse events. In the Zazzali
et al23 study, increased healthcare utilization and adverse events
associated with SCS use were reported, with adverse events further
stratified by the presence of chronic obstructive pulmonary disease.
Hypertension and type 2 diabetes were the most common SCS‐
associated adverse events that were more prevalent in this group
than in the non‐SCS group (62.9% vs 56.9% and 34.0% vs 28.4%,
respectively). Effect of cumulative SCS dosage was not reported.
Barry et al24 estimated the increased costs of SCS‐related morbidity,
and O'Neill et al26 estimated cost differences for patients using
maintenance steroids vs those not on maintenance steroids. Neither
study, however, collected information on initiation of treatment or
cumulative dosage. Other prior studies that examined HCRU and
costs did so over an average of 2 years, while previous studies on
clinical outcomes related to SCS exposure only considered an aver-
age exposure period of 6 months and none investigated the impact
of lifetime exposure. Unlike other studies,22-26 our study was based
on a large cohort of patients initiating SCS and explored the long‐
term impact of SCS exposure. Our study had a greater amount of
medical record history available (≥4 years for >75% of patients and
≥8 years for 50% of patients) than previous studies
(≤2 years),23,24,26 resulting in a more accurate determination of prior
SCS exposure. To accurately assess the impact of SCS‐associated
adverse outcomes on patients, we excluded patients with adverse
outcomes prior to index date (or first SCS dose). Patients in our
analyses had an average of 8.6 years of follow‐up in the SCS arm
and an average of 7.7 years in the non‐SCS arm. The average age of
our study patient population was 46 years, consistent with other
asthma study patient populations.6,10,18
Our study is the first to demonstrate that the costs associated
with SCS‐associated adverse outcomes increased over the years
according to SCS exposure, both overall and by SCS dosage. Incre-
mental yearly costs for SCS patients were 7% greater in the first
year and 1.5, 1.7, and 2.2 times greater by Years 5, 10, and 15,
respectively. This is consistent with incremental cumulative incidence
of the adverse outcomes in the SCS arm. Even though we also
observed slight increases in the adverse outcome cumulative inci-
dence in the non‐SCS arm, their longitudinal annual costs remained
flat, hinting potentially that the adverse outcomes observed in the
SCS arm could be more severe.
A UK study comparing nonasthma control (no exposure) with
GINA Step 2/3 patients (low exposure) and GINA Step 5 patients
(high exposure) estimated the annual cost (2013 values) of corticos-
teroid‐induced morbidity was £224 for low‐exposed group and
£1310 for high‐exposed group.25 It is unclear what the dosages were
in a study by Berry et al.25 In our study, we observed a £44.70,
£445.34, £1262.82, £1951.89, £1878.60, and £3283.70 incremental
SCS adverse outcome–associated average annual cost for SCS expo-
sure of 0.5‐<2.5 mg/day, 2.5‐<5.0 mg/day, 5.0‐<7.5 mg/day, 7.5‐
<15.0 mg/day, and ≥15.0 mg/day, respectively.
4.1 | Limitations
This study has several limitations. Although confounding by all mea-
sured patient characteristics was considered and addressed, as in all
observational research, we cannot exclude confounding by character-
istics we did not measure. As patients receiving SCS may be more
likely to be screened for comorbidities, an overestimation of comor-
bidities in this group relative to the non‐SCS group may
have occurred.
When looking at the different resource types, we observed a low
frequency of specialist consultations and A&E attendance. In the UK
healthcare system, chronic diseases are typically managed under pri-
mary care, and there is a clear tendency toward keeping as much
health care as possible at the primary care level. Therefore, our HCRU
results underestimated the burden that may be carried under
F IGURE 3 Mean annualized all‐cause
adverse outcome–associateda cost.
aExcluding asthma. Error bars represent
95% confidence interval. BMI, body mass
index; SCS, systemic corticosteroids
[Colour figure can be viewed at
wileyonlinelibrary.com]
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secondary or specialist care, where we could observe much greater
HCRU‐associated costs. This analysis excluded those who died due to
the adverse outcomes prior to the 15‐year mark and most likely under-
estimated incidence in the SCS arm more than in the non‐SCS arm.
For calculating costs for HCRU, we considered just the most
prevalent SCS‐related adverse outcomes rather than all possibilities.
Weight gain was identified as one of the key adverse outcomes for
SCS exposure. However, we could not link weight gain to any speci-
fic HCRU‐related outcomes to account for the cost. Therefore, an
inability to account for adverse health effects such as weight gain
led to the underestimation of the SCS burden.
We have considered a large set of covariates as potential con-
founders in the models. However, it is possible that information on
confounding factors was not available to use. The data we used
were registered during regular care, and not for research purposes.
As a result, disease history and onset could have been recorded
incorrectly or not at all. These input‐related variations could have led
to over‐ or underestimation of the observed associations.
5 | CONCLUSIONS
Our study is the first long‐term follow‐up study to examine SCS
adverse outcome burden and document the longitudinal detrimental
effect of SCS exposure among SCS initiators. We observed an increase
in cumulative incidence of adverse outcomes and associated
healthcare costs over time for SCS‐exposed patients. A positive
dosage–response relationship was observed between average daily
SCS exposure and cumulative SCS adverse outcomes incidence, asso-
ciated HCRU, and healthcare costs. Even low‐grade exposure to SCS
was related to long‐term detrimental effects of adverse outcomes.
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